Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?

A novel intraperitoneal chemotherapy regimen, trialled in the GOG 172 study, represents a new standard of care for patients with optimally resected stage III ovarian cancer, but should be offered on an individualised basis.

Download full article